Identify undiagnosed patients with kidney disease and track their care to improve health outcomes and avoid large, unpredictable medical bills.
Minimize the cost of care by knowing which members are high-risk and driving early intervention.
Succeed in this shifting space by deploying precisely-targeted care delivery to the patients who need it most.
"We see the partnership between Rogosin and pulseData as critical to our future. We believe the current CKD project is the beginning of many collaborative projects to come and we look forward to the continued growth and success of our relationship."
— Dr. Jeffrey Silberzweig, Chief Medical Officer of The Rogosin Institute
We partner closely with your providers to reduce the burden of chronic disease across your population by letting them know exactly who is at risk of acute events and which of their care workflows are working.
Using pulseData’s risk stratification tool, Vytalize Health is helping its primary care practices identify Medicare patients at risk of bad events, triage care, and allocate limited resources.
Today, pulseData announces that it was awarded a U.S. patent for a machine learning technology which detects the risk of renal decline, validating that there are repeatable, provable methods for predicting acute events. The implications of this technology are dramatic for the 37 million Americans that suffer from Chronic Kidney Disease (CKD).
pulseData, a New York City-based healthcare data science company, focused on predictive algorithms for Chronic Kidney Disease and other chronic diseases, today announced $16.5 million in Series A funding led by Bain Capital Private Equity and Two Bear Capital, with participation from Alumni Ventures Group and existing investors.
